Fujisawa Pharmaceutical Company, Ltd.

Norihiko Shimazaki

Masashi Hashimoto

Teruo Kyoto Oku

Tsutomu Toyonaka Teraji

Keiji Hemmi

Eishiro Todo

Takayuki Namiki

Hirokazu Tanaka

Osamu Nakaguti

Hitoshi Yamazaki

Shinya Watanabe

Akihiko Sawada

Takumi Yatabe

Yoshio Kawai

Yoshikuni Itoh

Yoshio Miyazaki

Michie Nakatuka

Osamu Nakaguchi

Heterobicyclic derivatives

Pyrido (2,3-B) pyrazine derivatives

This invention relates to certain 1-heterocycloalkylquinazolin-2,3-dione derivatives, certain pharmaceutically acceptable salts thereof, the process of making those compounds, and the method of using the compounds. The compounds and compositions display effects on the peripheral or central nervous system.

Quinazoline derivatives and their preparation

A compound of the formula: ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halogen, nitro, amino, protected amino, hydroxyamino, lower alkyl, hydroxy, protected hydroxy, sulfamoyl, carboxy, protected carboxy, mercapto, optionally substituted heterocyclic-carbonyl, optionally substituted heterocyclic-(lower)alkyl, lower alkylthio, hydroxy(lower)alkyl or protected hydroxy(lower)alkyl,

Compounds of the formula: ##STR1## are described wherein R.sup.1, R.sup.2, R.sup.3 and A are described in the claims. These compounds show significant dopamine receptor agonist activity.

Quinazoline derivatives

Diseases caused by platelet activating factor are prevented and treated by administration to a subject of a therapeutically effective amount of a piperazine compound of the formula: ##STR1## wherein R.sup.1 to R.sup.4 are as defined in the specification.

Piperazine compound as PAF-antagonist

The invention relates to a PAF-antagonist pharmaceutical composition comprising a compound of the formula: ##STR1## wherein R.sup.1 is pyridyl(lower)alkyl or thiazolyl(lower)alkyl,

New semicarbazide derivatives of the formula: ##STR1## wherein R.sup.1 is hydrogen,

Semicarbazide derivatives, processes for preparation thereof and

A compound of the formula: ##STR1## wherein R.sup.1 is hydrogen,

New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy, alkylthio or alkylsulfonyl;

Phospholipid derivatives, processes for use thereof and pharmaceutical

New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy or alkanoylamino;

Phospholipid derivatives, and pharmaceutical composition of the same

New phospholipid derivatives represented by the formula: ##STR1## wherein R.sup.1 is alkyl, alkoxy, alkylthio, ar(lower)alkoxy or alkanoylamino; R.sup.2 is lower alkyl or ar(lower)alkyl; n is an integer of 0 or 1; A is lower alkylene; R.sup.3 is pyridinio or a group of the formula: ##STR2## in which R.sup.5, R.sup.6 and R.sup.7 are each hydrogen or lower alkyl; and R.sup.4 is hydrogen or lower alkyl; and pharmaceutically acceptable salt thereof, which exhibit anti-hypertensive activity.

Certain glycerol-phosphoryl choline derivatives, compositions containing

New phosphate derivatives represented by the formula: ##STR1## wherein R.sup.1, R.sup.2, and R.sup.3 are each hydroxy, alkoxy, alkanoylamino or protected hydroxy;

Growing community of inventors

Ibaraki, Japan

Norihiko Shimazaki